약학회지 (YAKHAK HOEJI)

  • 제56권1호
  • /
  • Pages.35-41
  • /
  • 2012
  • /
  • 0377-9556(pISSN)
  • /
  • 2383-9457(eISSN)
대한약학회 (The Pharmaceutical Society of Korea)
권호 표지

SK-Hep1 인체 간암 세포에서 Luteolin에 의한 TRAIL 저항성 감소 효과

Sensitization of TRAIL-resistant SK-Hep1 Human Hepatocellular Carcinoma Cells by Luteolin

  • 김은영 (숙명여자대학교 약학대학) ;
  • 김안근 (숙명여자대학교 약학대학)
  • Kim, Eun-Young (College of Pharmacy, Sookmyung Women's University) ;
  • Kim, An-Keun (College of Pharmacy, Sookmyung Women's University)
  • 투고 : 2012.01.10
  • 심사 : 2012.02.22
  • 발행 : 2012.02.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

In this study, we examined the effect of luteolin to enhance TRAIL-induced anticancer effect in SK-Hep1 cells. We found that combined use of TRAIL with luteolin markedly enhanced the cytotoxicity compared to either agent alone by inducing apoptosis. Furthermore, combined treatment of TRAIL with luteolin significantly induced activation of death receptor pathway-related proteins as well as PARP-cleavage and activation of effector caspases. Also, our result indicated that upregulation of DR4 and DR5 by luteolin combination may contribute to enhanced susceptibility of SK-Hep1 cells to TRAIL.

키워드

참고문헌

  1. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z. and Schwall, R. H. : Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155 (1999).
  2. Roth, W., Isenmann, S., Naumann, U., Kugler, S., Bahr, M., Dichgans, J., Ashkenazi, A. and Weller, M. : Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem. Bioph. Res. Co. 265, 479 (1999).
  3. Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R. G., Rauch, C. T., Schuh, J. C. and Lynch, D. H. : Tumoricidal activity of tumor necrosis factorrelated apoptosis-inducing ligand in vivo. Nat. Med. 5, 157 (1999).
  4. Hinz, S., Trauzold, A., Boenicke, L., Sandberg, C., Beckmann, S., Bayer, E., Walczak, H., Kalthoff, H. and Ungefroren, H. : Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 19, 5477 (2000).
  5. Zhang, Y. and Zhang, B. : TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol. Cancer Res. 6, 1861 (2008).
  6. Van Geelen, C. M., Pennarun, B., Le, P. T., de Vries, E. G. and de Jong, S. : Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. BMC Cancer 11, 39 (2011).
  7. Zhang, L. and Fang, B. : Mechanisms of resistance to TRAILinduced apoptosis in cancer. Cancer Gene Ther. 12, 228 (2004).
  8. Khanbolooki, S., Nawrocki, S. T., Arumugam, T., Andtbacka, R., Pino, M. S., Kurzrock, R., Logsdon, C. D., Abbruzzese, J. L. and McConkey, D. J. : Nuclear $factor-{\kappa}B$ maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther. 5, 2251 (2006).
  9. Van Geelen, C. M. M., de Vries, E. G. E. and de Jong, S. :Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist. Updates 7, 345 (2004).
  10. Birt, D. F., Hendrich, S. and Wang, W. : Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol. Therapeut. 90, 157 (2001).
  11. Greenwald, P., Clifford, C. K. and Milner, J. A. : Diet and cancer prevention. Eur. J. Cancer 37, 948 (2001).
  12. Kawamori, T., Lubet, R., Steele, V. E., Kelloff, G. J., Kaskey, R. B., Rao, C. V. and Reddy, B. S. : Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res. 59, 597 (1999).
  13. De Flora, S. and Ferguson, L. R. : Overview of mechanisms of cancer chemopreventive agents. Mutat. Res. 591, 8 (2005).
  14. Malik, A., Afaq, F., Sarfaraz, S., Adhami, V. M., Syed, D. N. and Mukhtar, H. : Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. P. Natl. Acad. Sci. USA 102, 14813 (2005).
  15. Lopez-Lazaro, M. : Distribution and biological activities of the flavonoid luteolin. Mini-Rev. Med. Chem. 9, 31 (2009).
  16. Jang, S., Kelley, K. W. and Johnson, R. W. : Luteolin reduces IL- 6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. P. Natl. Acad. Sci. USA 105, 7534 (2008).
  17. Wolfle, U., Esser, P. R., Simon-Haarhaus, B., Martin, S. F., Lademann, J. and Schempp, C. M. : UVB-induced DNA damage, generation of reactive oxygen species, and inflammation are effectively attenuated by the flavonoid luteolin in vitro and in vivo. Free Radical Bio. Med. 50, 1081 (2011).
  18. Zhu, L.-H., Bi, W., Qi, R.-B., Wang, H.-D., Wang, Z.-G., Zeng, Q., Zhao, Y.-R. and Lu, D.-X. : Luteolin reduces primary hippocampal neurons death induced by neuroinflammation. Neurol. Res. 33, 927 (2011).
  19. Lin, Y., Shi, R., Wang, X. and Shen, H. M. : Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr. Cancer Drug Tar. 8, 634 (2008).
  20. Seelinger, G., Merfort, I., Wolfle, U. and Schempp, C. M. : Anticarcinogenic effects of the flavonoid luteolin. Molecules 13, 2628 (2008).
  21. Shi, R. X., Ong, C. N. and Shen, H. M. : Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res. 65, 7815 (2005).
  22. Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L. and Henson, P. M. : Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148, 2207 (1992).
  23. Vermes, I., Haanen, C., Steffens-Nakken, H. and Reutellingsperger, C. : A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184, 39 (1995).
  24. Budihardjo, I., Oliver, H., Lutter, M., Luo, X. and Wang, X. : Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Bi. 15, 269 (1999).
  25. Oliver, F. J., de la Rubia, G., Rolli, V., Ruiz-Ruiz, M. C., de Murcia, G. and Murcia, J. M.-d. : Importance of poly(ADPribose) polymerase and its cleavage in apoptosis. J. Biol. Chem. 273, 33533 (1998).
  26. Hengartner, M. O. : The biochemistry of apoptosis. Nature 407, 770 (2000).
  27. Schneider, P., Thome, M., Burns, K., Bodmer, J.-L., Hofmann, K., Kataoka, T., Holler, N. and Tschopp, J. : TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate $NF-{\kappa}B$. Immunity 7, 831 (1997).
  28. Wang, S. and El-Deiry, W. S. : TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22, 8628 (2003).
  29. Horinaka, M., Yoshida, T., Shiraishi, T., Nakata, S., Wakada, M., Nakanishi, R., Nishino, H., Matsui, H. and Sakai, T. : Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 24, 7180 (2005).